Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas.

Autor: Pittman JE; Department of Pediatrics, Washington University, St. Louis, MO, United States. Electronic address: jpittman@wustl.edu., Skalland MS; Seattle Children's Hospital, Seattle, WA, United States. Electronic address: michelle.skalland@seattlechildrens.org., Sagel SD; Department of Pediatrics, Children's Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: Scott.Sagel@childrenscolorado.org., Ramsey BW; Department of Pediatrics, University of Washington, Seattle, WA, United States; Seattle Children's Hospital, Seattle, WA, United States. Electronic address: bonnie.ramsey@seattlechildrens.org., Mayer-Hamblett N; Department of Pediatrics, University of Washington, Seattle, WA, United States; Seattle Children's Hospital, Seattle, WA, United States; Department of Biostatistics, University of Washington, Seattle, WA, United States. Electronic address: nicole.hamblett@seattlechildrens.org., Retsch-Bogart GZ; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, United States. Electronic address: gzrb@med.unc.edu.
Jazyk: angličtina
Zdroj: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2022 Nov; Vol. 21 (6), pp. 946-949. Date of Electronic Publication: 2022 Mar 05.
DOI: 10.1016/j.jcf.2022.02.015
Abstrakt: Chronic azithromycin improves outcomes in cystic fibrosis (CF), but its mechanism of action is unclear. The OPTIMIZE trial demonstrated improvement in time to first pulmonary exacerbation in children with new Pseudomonas treated with azithromycin. Azithromycin effect on systemic markers of inflammation over 18 months was assessed by change from baseline for high-sensitivity C-reactive protein, myeloperoxidase, calprotectin and absolute neutrophil count in the OPTIMIZE population. Subjects treated with chronic azithromycin or placebo had samples collected at baseline, 39 and 78 weeks of treatment. In 129 subjects, a significant decrease in high-sensitivity C-reactive protein was present at 39 weeks in the azithromycin group compared to placebo, but no significant difference between the groups at 78 weeks. No differences in change from baseline in myeloperoxidase, calprotectin or absolute neutrophil count were present at either time point. This supports the concept of a transient immunomodulatory effect for chronic azithromycin therapy in children with CF.
Competing Interests: Declaration of Competing Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare no competing interests.
(Copyright © 2022. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: